Dynamic Relapse Prediction by Peripheral Blood WT1mRNA after Allogeneic Hematopoietic Cell Transplantation for Myeloid Neoplasms

被引:0
|
作者
Nakako, Soichiro [1 ]
Okamura, Hiroshi [1 ,2 ]
Yokota, Isao [3 ]
Umemoto, Yukari [1 ]
Horiuchi, Mirei [1 ]
Sakatoku, Kazuki [1 ]
Ido, Kentaro [1 ,2 ]
Makuuchi, Yosuke [1 ]
Kuno, Masatomo [1 ]
Takakuwa, Teruhito [1 ]
Nishimoto, Mitsutaka [1 ]
Hirose, Asao [1 ]
Nakamae, Mika [1 ,2 ]
Nakashima, Yasuhiro [1 ]
Koh, Hideo [4 ]
Hino, Masayuki [1 ,2 ]
Nakamae, Hirohisa [1 ]
机构
[1] Osaka Metropolitan Univ, Grad Sch Med, Dept Hematol, 1-4-3 Asahi machi,Abeno ku, Osaka 5458585, Japan
[2] Osaka Metropolitan Univ, Grad Sch Med, Dept Lab Med & Med Informat, Osaka, Japan
[3] Hokkaido Univ, Grad Sch Med, Dept Biostat, Hokkaido, Japan
[4] Osaka Metropolitan Univ, Grad Sch Med, Dept Prevent Med & Environm Hlth, Osaka, Japan
来源
TRANSPLANTATION AND CELLULAR THERAPY | 2024年 / 30卷 / 11期
基金
日本学术振兴会;
关键词
Allogeneic stem cell; transplantation; Dynamic prediction; WT1mRNA; Biomarker; MINIMAL RESIDUAL DISEASE; WT1; MESSENGER-RNA; MYELODYSPLASTIC SYNDROME; LEUKEMIA; LANDMARKING; VALIDATION; MORTALITY; INDEX; IPSS;
D O I
10.1016/j.jtct.2024.08.008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although various relapse prediction models based on pretransplant information have been reported, they cannot update the predictive probability considering post-transplant patient status. Therefore, these models are not appropriate for deciding on treatment adjustment and preemptive intervention during post-transplant follow-up. A dynamic prediction model can update the predictive probability by considering the information obtained during follow-up. This study aimed to develop and assess a dynamic relapse prediction model after allogeneic hematopoietic cell transplantation (allo-HCT) for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) using peripheral blood Wilms' tumor 1 messenger RNA (WT1mRNA). We retrospectively analyzed patients with AML or MDS who underwent allo-HCT at our institution. To develop dynamic models, we employed the landmarking supermodel approach, using age, refined disease risk index, conditioning intensity, and number of transplantations as pretransplant covariates and both pre- and post-transplant peripheral blood WT1mRNA levels as time-dependent covariates. Finally, we compared the predictive performances of the conventional and dynamic models by area under the time-dependent receiver operating characteristic curves. A total of 238 allo-HCT cases were included in this study. The dynamic model that considered all pretransplant WT1mRNA levels and their kinetics showed superior predictive performance compared to models that considered only pretransplant covariates or factored in both pretransplant
引用
收藏
页码:1088e1 / 1088e12
页数:12
相关论文
共 50 条
  • [1] Monitoring and Prevention of Relapse after Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies
    Bacher, Ulrike
    Talano, Julie-An
    Bishop, Michael R.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (01) : S62 - S73
  • [2] Genetic features and outcomes of allogeneic transplantation in patients with WT1-mutated myeloid neoplasms
    Baranwal, Anmol
    Basmaci, Rami
    He, Rong
    Viswanatha, David
    Greipp, Patricia
    Murthy, Hemant S.
    Foran, James
    Palmer, Jeanne
    Hogan, William J.
    Litzow, Mark R.
    Hefazi, Mehrdad
    Mangaonkar, Abhishek
    Shah, Mithun Vinod
    Al-Kali, Aref
    Alkhateeb, Hassan B.
    BLOOD ADVANCES, 2024, 8 (03) : 562 - 570
  • [3] The prevention of disease relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia
    Maffini, Enrico
    Ursi, Margherita
    Barbato, Francesco
    Dicataldo, Michele
    Roberto, Marcello
    Campanini, Elena
    Dan, Elisa
    De Felice, Francesco
    De Matteis, Serena
    Storci, Gianluca
    Bonafe, Massimiliano
    Arpinati, Mario
    Bonifazi, Francesca
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [4] The Proportional Relationship Between Pretransplant WT1 mRNA Levels and Risk of Mortality After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Not in Remission
    Ido, Kentaro
    Nakamae, Mika
    Koh, Hideo
    Okamura, Hiroshi
    Nanno, Satoru
    Nishimoto, Mitsutaka
    Takeoka, Yasunobu
    Hirose, Asao
    Nakashima, Yasuhiro
    Hashimoto, Yoshinori
    Nakane, Takahiko
    Hino, Masayuki
    Nakamae, Hirohisa
    TRANSPLANTATION, 2019, 103 (10) : 2201 - 2210
  • [5] Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment
    Kreidieh, Firas
    Abou Dalle, Iman
    Moukalled, Nour
    El-Cheikh, Jean
    Brissot, Eolia
    Mohty, Mohamed
    Bazarbachi, Ali
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 116 (03) : 330 - 340
  • [6] WT1-guided pre-emptive therapy after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia
    Arai, Shota
    Tachibana, Takayoshi
    Izumi, Akihiko
    Takeda, Takaaki
    Tamai, Yotaro
    Sato, Shuku
    Hashimoto, Chizuko
    Fujimaki, Katsumichi
    Ishii, Ryuji
    Kabasawa, Noriyuki
    Hirasawa, Akira
    Inoue, Yasuyuki
    Tanaka, Masatsugu
    Suzuki, Takahiro
    Nakajima, Hideaki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 120 (03) : 337 - 346
  • [7] Peripheral Blood WT1 Expression Predicts Relapse in AML Patients Undergoing Allogeneic Stem Cell Transplantation
    Malagola, Michele
    Skert, Cristina
    Ruggeri, Giuseppina
    Turra, Alessandro
    Ribolla, Rossella
    Cancelli, Valeria
    Cattina, Federica
    Alghisi, Elisa
    Bernardi, Simona
    Perucca, Simone
    Di Palma, Andrea
    Borlenghi, Erika
    Pagani, Chiara
    Rossi, Giuseppe
    Caimi, Luigi
    Russo, Domenico
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [8] Hypomethylating Agents for Relapse after Allogeneic Hematopoietic Cell Transplantation in Myeloid Malignancies: A Case Series and Review of the Literature
    Im, Annie
    Raptis, Anastasios
    Hou, Jing-Zhou
    Tompkins, Cheryl
    Winfield, Melissa
    Guay, Mary
    Boyiadzis, Michael
    Agha, Mounzer
    ACTA HAEMATOLOGICA, 2016, 135 (04) : 232 - 237
  • [9] Low-dose azacitidine for relapse prevention after allogeneic hematopoietic cell transplantation in children with myeloid malignancies
    Oshrine, Benjamin R.
    Shyr, David
    Hale, Gregory
    Petrovic, Aleksandra
    PEDIATRIC TRANSPLANTATION, 2019, 23 (04)
  • [10] WT1 and TP53 as valuable diagnostic biomarkers for relapse after hematopoietic stem cell transplantation in acute myeloid leukemia
    Asghari-Ghomi, Ali
    Fallahian, Faranak
    Garavand, Javad
    Mohammadi, Mohammad Hossein
    MOLECULAR BIOLOGY REPORTS, 2024, 51 (01)